| 摘要 |
The use of compounds described as bisphosphonates selected from the group consisting of: alendronate, etidronate (1-hydroxy-ethidene-bisphosphonic acid), pamidronate (3-amino-1-hydroxypropyildiene-1,1-diphosphanate), risedronate (2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonic acid), clodronate (dichloromethylene-bisphosphonic acid), tiludronate (chloro-4-phenylthiomethylidene-bisphosphonic acid), ibandronic acid (1-hydroxy-3-(methylpentylamino)-propylidene-bisphosphonic acid and pharmaceutically acceptable salts thereof for treating or preventing bone loss associated with immunosuppressive therapy.
|
